頭頚部悪性腫瘍に対するNK-631(Pepleomycin)の臨床効果

概要

論文の詳細を見る
We administered NK-631 to 40 patients with head and neck tumor by intra-arterial infusion in 2, by intravenous administration in 38. The tumor was squamous cell carcinoma in 33 cases and malignant lymphoma in 7. Anatomical site of the tumor in 40 was as follows: larynx and mesopharynx 10 respectively, oral cavity 9, nose and paranasal sinuses 5, hypopharynx 4, ear and nasopharynx 1, respectively. Excellent response was obtained in 7 cases and good response in 11 cases of squamous cell carcinoma. The response rate was 58% or 18/31. Excellent response was obtained in 4 and good response in 2 with malignant lymphoma. The response rate was 86% or 6/7. Effect of NK-631 appears to be almost the same as is seen with Bleomycin treatment. NK-631 was most effective in malignant lymphoma as well as in well differentiated squamous cell carcinoma.Eruption and thickening of the skin were the most common toxic effects and such were evident in about 30% of all patients. NK-631 was less toxic for the lung as compared with Bleomycin.
耳鼻咽喉科臨床学会の論文